Five Prime (FPRX)

Company Description

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.

 

COMPANY ADDRESS
Two Corporate Drive
South San Francisco, CA 94080
United States

COMPANY PHONE
415-365-5600

COMPANY WEBSITE


Get BioInvest's perspective on Five Prime’s CEO

Latest Company News

Five Prime Therapeutics Inc (FPRX) Shares Bought by Teachers Advisors LLC The Cerbat Gem - 6 hours ago Five Prime Therapeutics logo Teachers Advisors LLC boosted its position in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Reviewed By Analysts - The De Soto Edge [...]
Tue, Apr 25, 2017 1:18:00 PM, Continue reading at the source
Analyst Views And Outlook On Two Stocks: Five Prime Therapeutics, Inc. (FPRX ... Post Analyst - 7 hours ago Five Prime Therapeutics, Inc. (FPRX) failed to surprise the stock market in its last reported earnings when it earned -$0.73 a piece versus the consensus-estimated -$0.57. [...]
Tue, Apr 25, 2017 12:11:00 PM, Continue reading at the source
A Look Ahead For 2 Stocks: Five Prime Therapeutics, Inc. (NASDAQ:FPRX), CEL ... Post Analyst - Apr 24, 2017 Five Prime Therapeutics, Inc. (FPRX) has made its way to a 12-month decline of -32.58%. Turning to CEL-SCI Corporation (NYSE:CVM), its shares were trading at $0.09 a retreat of $0, on the trading floor. [...]
Mon, Apr 24, 2017 11:48:00 AM, Continue reading at the source
Five Prime Therapeutics Inc. (FPRX) Settles Into New 52-Week Low on April 21 ... Equities.com - Apr 21, 2017 Shares of Five Prime Therapeutics Inc. (FPRX) sank into a new 52-week low yesterday, and could be a company to watch at the open. Stock Returns: Geron Corporation (NASDAQ:GERN) is Beating Five Prime ... - CML News Five Prime Therapeutics (FPRX) Getting Positive Media Coverage, AlphaOne Reports - The Cerbat Gem [...]
Fri, Apr 21, 2017 9:30:00 PM, Continue reading at the source
Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and ... Nasdaq - Apr 20, 2017 SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will ... Dimensional Fund Advisors LP Raises Stake in Five Prime Therapeutics Inc (FPRX) - The Cerbat Gem [...]
Thu, Apr 20, 2017 8:03:00 PM, Continue reading at the source
Five Prime Therapeutics: Initiating Coverage With A Buy Rating And A $56 Price ... Seeking Alpha - Mar 31, 2017 Five Prime Therapeutics (FPRPX) is a San Francisco-based immune-oncology company that is developing novel monoclonal antibodies for the treatment of various cancers. [...]
Fri, Mar 31, 2017 1:13:00 AM, Continue reading at the source
Five Prime At Lows With Looming Catalysts Seeking Alpha - Mar 27, 2017 Company has a diversified pipeline with several promising clinical candidates, a validating partnership with Bristol-Myers Squibb, and a large cash position. [...]
Mon, Mar 27, 2017 4:18:00 PM, Continue reading at the source
Five Prime Therapeutics Announces Executive Changes GlobeNewswire (press release) - Mar 20, 2017 SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Other Events - Market Exclusive Stock Returns: Five Prime Therapeutics Inc (NASDAQ:FPRX) is Beating Intrexon ... - CML News [...]
Mon, Mar 20, 2017 8:05:00 PM, Continue reading at the source
Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2016 Results ... Seeking Alpha - Feb 24, 2017 Good day, ladies and gentlemen and welcome to the Five Prime Therapeutics Fourth Quarter And Fiscal Year 2016 Earnings Call. Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results - GlobeNewswire (press release) [...]
Fri, Feb 24, 2017 3:45:00 AM, Continue reading at the source
Five Prime Therapeutics Announces Key Executive Promotions GlobeNewswire (press release) - Sep 20, 2016 SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... [...]
Tue, Sep 20, 2016 8:46:00 PM, Continue reading at the source